Adelaide Research & Scholarship: Search

Search

Results 1-8 of 8 (Search time: 0.002 seconds).

previous
1
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2003	Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase	Branford, S.; Rudzki, Z.; Harper, A.; Grigg, A.; Taylor, K.; Durrant, S.; Arthur, C.; Browett, P.; Schwarer, A.; Ma, D.; Seymour, J.; Bradstock, K.; Joske, D.; Lynch, K.; Gathmann, I.; Hughes, T.
	2002	High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance	Branford, S.; Rudzki, Z.; Walsh, S.; Grigg, A.; Arthur, C.; Taylor, K.; Herrmann, R.; Lynch, K.; Hughes, T.
	2003	Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia	Hughes, T.; Kaeda, J.; Branford, S.; Rudzki, Z.; Hochhaus, A.; Hensley, M.; Gathmann, I.; Bolton, A.; van Hoomissen, I.; Goldman, J.; Radich, J.
	2002	Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene	Branford, S.; Hughes, T.; Rudzki, Z.
	2003	Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR	Hui, C.; Goh, K.; White, D.; Branford, S.; Grigg, A.; Seymour, J.; Kwan, Y.; Walsh, S.; Hoyt, R.; Trickett, A.; Rudzki, Z.; Ma, D.; To, L.; Hughes, T.
	1999	Monitoring chronic myeloid leukaemia therapy by real time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics	Branford, S.; Hughes, T.; Rudzki, Z.
	2003	Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis	Branford, S.; Rudzki, Z.; Walsh, S.; Parkinson, I.; Grigg, A.; Szer, J.; Taylor, K.; Hermann, R.; Seymour, J.; Arthur, C.; Joske, D.; Lynch, K.; Hughes, T.
	2007	BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria	Branford, S.; Seymour, J.; Grigg, A.; Arthur, C.; Rudzki, Z.; Lynch, K.; Hughes, T.